ASCO 2013 afatinib* and nintedanib* data story

Watch a video round-up of the afatinib* and nintedanib* Phase III data presented at the ASCO 2013 Annual Meeting.

Importance of EGFR Mutation Testing

Interview with Dr Vera Hirsh Associate Professor, McGill University Department of Medical Oncology Royal Victoria Hospital, Montreal, Canada

LUX-Lung 3 Results - Prof Thomas Lynch

Interview with Prof Thomas J. Lynch, MD Director of Yale Cancer Center, New Haven, USA

LUX-Lung 3 Trial Design

Interview with Prof Tony Shu Kam Mok, MD Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong

LUX-Lung 6 and other Afatinib Trials

Interview with Prof James-Chih-Hsin Yang Director of the Cancer Research Center, College of Medicine, National Taiwan University, Taipei, Taiwan

LUX-Lung 7 & 8 Trials

Interview with Prof Thomas J. Lynch, MD Director of Yale Cancer Center, New Haven, USA

Afatinib lung cancer treatment - NSCLC with EGFR mutation

Interview with Prof Thomas J. Lynch, MD Director of Yale Cancer Center, New Haven, USA

Lung cancer biomarkers

Interview with Prof Thomas J. Lynch, MD Director of Yale Cancer Center, New Haven, USA

Ovarian Cancer Research and New Treatment Options

Interview with Jonathan Ledermann, BSc, MD, FRCP Cancer Research UK and UCL Cancer Institute London, UK

Ovarian Cancer Symptoms and Characteristics

Interview with Ken Swenerton, MD, FRCPC Cancer Medicine in Gynecology Clinical Professor, Faculty of Medicine, University of British Columbia

Ovarian Cancer Prognosis & Late Diagnosis

Interview with Professor Ignace Vergote Chairman of the Leuven Cancer Institute

Ovarian Cancer Treatment - Targeted Therapies

Interview with Ken Swenerton, MD, FRCPC Cancer Medicine in Gynecology Clinical Professor, Faculty of Medicine, University of British Columbia

Head and Neck Cancer Incidence and Prognosis

Interview with Ezra Cohen, MD Associate Professor of Medicine University of Chicago Medical Center

Head and Neck Cancer Treatments & Targeted Therapies

Interview with Ezra Cohen, MD Associate Professor of Medicine University of Chicago Medical Center

Afatinib Head and Neck Cancer Trials

Interview with Ezra Cohen, MD Associate Professor of Medicine University of Chicago Medical Center

Angiokinase inhibitors in lung cancer

Interview with Marianne Nicolson, MD, FRCP Consultant Medical Oncologist, Aberdeen Royal Infirmary, Aberdeen, Scotland

Targeted lung cancer treatment

Improving outcomes in lung cancer

Personalising cancer care and the future of cancer treatments

Interview with John Heymach, MD, PhD Associate Professor, MD Anderson Cancer Center, Houston, Texas, USA

Personalised Cancer Treatment - Cancer as Chronic Disease

Interview with Kathleen Pritchard, MD, FRCPC Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada

Non small cell lung cancer overview

Interview with David Ross Camidge, MD, PhD Assistant Professor, University of Colorado, Denver, Colorado, USA

EGFR Mode of Action

Volasertib* Plk 1 inhibitor - Oncology compound

Volasertib* (compound code BI 6727) is an investigational, potent, and selective inhibitor in vitro of PLK1, an important regulator of the cell cycle.